市场调查报告书

骨质疏松症治疗药的全球市场

Osteoporosis Therapeutics

出版商 Global Industry Analysts, Inc. 商品编码 912424
出版日期 内容资讯 英文 340 Pages
商品交期: 最快1-2个工作天内
价格
骨质疏松症治疗药的全球市场 Osteoporosis Therapeutics
出版日期: 2020年09月01日内容资讯: 英文 340 Pages
简介

本报告提供全球骨质疏松症治疗药市场概要,汇整趋势·发展的影响因素分析,竞争企业与市场占有率,世界及各地区·主要国家的市场规模的变化与预测,主要企业简介等资讯。

第1章 调查手法

第2章 摘要整理

  • 市场概要
    • 全球市场的企业占有率
    • 全球骨质疏松症治疗药市场上企业占有率方案
  • 主要企业
  • 市场趋势与发展因素
  • 全球市场预测

第3章 市场分析

  • 各地区市场分析
    • 美国
    • 加拿大
    • 日本
    • 中国
    • 欧洲
    • 法国
    • 德国
    • 义大利
    • 英国
    • 西班牙
    • 俄罗斯
    • 其他欧洲
    • 亚太地区
    • 澳洲
    • 印度
    • 韩国
    • 其他亚太地区
    • 南美
    • 阿根廷
    • 巴西
    • 墨西哥
    • 其他南美国家
    • 中东
    • 伊朗
    • 以色列
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国
    • 其他中东
    • 非洲

第4章 竞争企业

  • ALLERGAN PLC
  • AMGEN
  • ELI LILLY AND COMPANY
  • F. HOFFMANN-LA ROCHE AG
  • GLAXOSMITHKLINE PLC
  • MERCK KGAA
  • NOVARTIS INTERNATIONAL AG
  • NOVO NORDISK A/S
  • PFIZER
  • TEVA PHARMACEUTICAL INDUSTRIES

第5章 调查资料

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: MCP-1229

The global market for Osteoporosis Therapeutics is projected to reach US$13.3 billion by 2025, driven by rising awareness over the growing problem of osteoporosis and the ensuing emphasis on early diagnosis and treatment. With the percentage share of people aged 60 plus in the global population mix forecast to reach 21.5% from the current 12.7%, burden of osteoporosis will increase significantly accounting for over 75% of all fractures among the elderly. Although largely preventable, fractures result in long-term injuries, severe pain, long-term disability and high mortality. In the Europe, India, Japan and the United States over 150 million people live with osteoporosis, a number poised to rise significantly in the coming years. Medical emphasis on prevention and early diagnosis will therefore gain prominence providing the cornerstone for growth in the market. As losses in bone mineral density (BMD) is high in the elderly, aging population remains a key growth catalyst, with the risk of osteoporotic hip, vertebral and wrist fracture tripling with age. Economic burden of osteoporotic fractures (OFs) will grow bigger in sync with the aging population growth from 729.3 million people in the age group 65+ in 2020 to over 852.5 million by 2025. The cost of long-term disability from osteoporosis is huge since over 25% of elderly suffering from hip fracture will require permanent nursing home care. Also driving prevalence rates are factors such as rising incidence of vitamin D deficiencies, anorexia nervosa, growing cancer epidemic and increase in the number of patients undergoing chemotherapy and/or using glucocorticoids both of which tend to accelerate the loss of bone mineral density.

The scenario offers a robust outlook for osteoporosis therapeutics. Osteoporosis therapeutics are mainly targeted at reducing the risk of fractures, and are categorized into two main drug categories, named antiresorptive or anabolic. Antiresorptive drugs reduce bone resorption and include mainly bisphosphonates, estrogens, estrogen agonist/ antagonists [EAAs], calcitonin, and denosumab. Anabolic drugs work by increasing bone formation and include teriparatide. Few of the approved drugs for osteoporosis include EVISTA (Selective Estrogen-Receptor Modulator (SERM); DUAVIVE (Estrogen and Selective Estrogen-Receptor Modulator (SERM); FORTEO (Parathyroid Hormone); ACLASTA/ACTONEL (Bisphosphonates); PROLIA (RANK ligand inhibitor); CLIMARA (Hormonal Therapy - Transdermal). Bisphosphonates represent the largest category of drugs for the treatment of osteoporosis and is recommended as the first line of treatment for the prevention of osteoporosis in postmenopausal women, men, and GIO patients. The market also stands to benefit from growing movement in the medical community over the need for further research for safe use of long-term osteoporosis drug therapies for fracture prevention. This will help attract funding support and will speed up the development of new treatments. The United States and Europe represent large markets worldwide with a combined share of 67.2% of the market. China ranks as the fastest growing market with a CAGR of 5.9% over the analysis period supported by attractive reimbursement policies. The national health system and private insurers together reimburse over 75% to 875% of inpatient osteoporosis treatments and 35% to 45% of outpatient care. Traditional Chinese medicine enjoys over is 80% reimbursement.

Competitors identified in this market include, among others,

  • Alergan Plc.
  • Amgen, Inc.
  • Chugai pharmaceutical
  • Daiichi Sankyo Co., Ltd.
  • Egalet Corporation
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.;

TABLE OF CONTENTS

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • A Prelude to Osteoporosis
    • Growing Geriatric Population and Rising Incidence of Osteoporosis Drive the Global Osteoporosis Market
    • Developed Regions Dominate the Global Market, Developing to Witness Fastest Growth
    • Bisphosphonates - The Largest Category of Drugs for Treating Osteoporosis
    • Approved Drugs for Treatment of Osteoporosis
    • Select Recent Osteoporosis Drug Approvals
    • Global Competitor Market Shares
    • Osteoporosis Therapeutics Competitor Market Share Scenario Worldwide by Leading Players (in %):
    • Sales of Leading Osteoporosis Therapeutics:
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Incidence of Osteoporosis Augurs Well for Osteoporosis Therapeutics
    • Global Osteoporosis Prevalence by Country/Region (2012 & 2022P): Number of People with Osteoporosis in Millions for US, EU, Japan, China and India
    • % of Women Affected by Osteoporosis
    • Osteoporosis - Factsheet
    • Osteoporosis in Men
    • Rising Geriatric Population and the Associated Bone Health Issues to Drive Market Gains
    • Global Population of 65+ Individuals (In 000s) by Region for the Years 2015, 2020 &
    • Rising Prevalence of Osteoporosis in Post-menopausal Women Propels Market Growth
    • Changing Lifestyle Impacting Bone Health
    • Recommended Daily Intake of Calcium and Vitamin D
    • Increasing Awareness Related to Osteoporosis Care
    • New Product Launches Foster Market Growth
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Osteoporosis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through
    • TABLE 2: World Historic Review for Osteoporosis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 3: World 15-Year Perspective for Osteoporosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Bisphosphonates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through
    • TABLE 5: World Historic Review for Bisphosphonates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 6: World 15-Year Perspective for Bisphosphonates by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Parathyroid Hormone Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through
    • TABLE 8: World Historic Review for Parathyroid Hormone Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 9: World 15-Year Perspective for Parathyroid Hormone Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Calcitonin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through
    • TABLE 11: World Historic Review for Calcitonin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 12: World 15-Year Perspective for Calcitonin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Selective Estrogen Inhibitors Modulator (SERM) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through
    • TABLE 14: World Historic Review for Selective Estrogen Inhibitors Modulator (SERM) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 15: World 15-Year Perspective for Selective Estrogen Inhibitors Modulator (SERM) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Rank Ligand Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through
    • TABLE 17: World Historic Review for Rank Ligand Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 18: World 15-Year Perspective for Rank Ligand Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through
    • TABLE 20: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 21: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 22: World Current & Future Analysis for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through
    • TABLE 23: World Historic Review for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 24: World 15-Year Perspective for Injectables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 25: World Current & Future Analysis for Other Routes of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through
    • TABLE 26: World Historic Review for Other Routes of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 27: World 15-Year Perspective for Other Routes of Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • GEOGRAPHIC MARKET ANALYSIS
  • UNITED STATES
    • TABLE 28: USA Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 29: USA Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 30: USA 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2020 & 2027
    • TABLE 31: USA Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 32: USA Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 33: USA 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 34: Canada Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 35: Canada Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 36: Canada 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2020 & 2027
    • TABLE 37: Canada Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 38: Canada Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 39: Canada 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 40: Japan Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 41: Japan Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 42: Japan 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2020 & 2027
    • TABLE 43: Japan Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 44: Japan Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 45: Japan 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 46: China Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 47: China Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 48: China 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2020 & 2027
    • TABLE 49: China Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 50: China Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 51: China 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 52: Europe Current & Future Analysis for Osteoporosis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through
    • TABLE 53: Europe Historic Review for Osteoporosis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 54: Europe 15-Year Perspective for Osteoporosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 55: Europe Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 56: Europe Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 57: Europe 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2020 & 2027
    • TABLE 58: Europe Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 59: Europe Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 60: Europe 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 61: France Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 62: France Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 63: France 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2020 & 2027
    • TABLE 64: France Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 65: France Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 66: France 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 67: Germany Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 68: Germany Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 69: Germany 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2020 & 2027
    • TABLE 70: Germany Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 71: Germany Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 72: Germany 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 73: Italy Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 74: Italy Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 75: Italy 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2020 & 2027
    • TABLE 76: Italy Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 77: Italy Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 78: Italy 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 79: UK Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 80: UK Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 81: UK 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2020 & 2027
    • TABLE 82: UK Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 83: UK Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 84: UK 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2020 & 2027
  • SPAIN
    • TABLE 85: Spain Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 86: Spain Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 87: Spain 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2020 & 2027
    • TABLE 88: Spain Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 89: Spain Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 90: Spain 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2020 & 2027
  • RUSSIA
    • TABLE 91: Russia Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 92: Russia Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 93: Russia 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2020 & 2027
    • TABLE 94: Russia Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 95: Russia Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 96: Russia 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 97: Rest of Europe Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 98: Rest of Europe Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 99: Rest of Europe 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2020 & 2027
    • TABLE 100: Rest of Europe Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 101: Rest of Europe Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 102: Rest of Europe 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 103: Asia-Pacific Current & Future Analysis for Osteoporosis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through
    • TABLE 104: Asia-Pacific Historic Review for Osteoporosis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 105: Asia-Pacific 15-Year Perspective for Osteoporosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
    • TABLE 106: Asia-Pacific Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 107: Asia-Pacific Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 108: Asia-Pacific 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2020 & 2027
    • TABLE 109: Asia-Pacific Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 110: Asia-Pacific Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 111: Asia-Pacific 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2020 & 2027
  • AUSTRALIA
    • TABLE 112: Australia Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 113: Australia Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 114: Australia 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2020 & 2027
    • TABLE 115: Australia Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 116: Australia Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 117: Australia 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2020 & 2027
  • INDIA
    • TABLE 118: India Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 119: India Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 120: India 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2020 & 2027
    • TABLE 121: India Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 122: India Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 123: India 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2020 & 2027
  • SOUTH KOREA
    • TABLE 124: South Korea Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 125: South Korea Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 126: South Korea 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2020 & 2027
    • TABLE 127: South Korea Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 128: South Korea Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 129: South Korea 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2020 & 2027
  • REST OF ASIA-PACIFIC
    • TABLE 130: Rest of Asia-Pacific Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 131: Rest of Asia-Pacific Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 132: Rest of Asia-Pacific 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2020 & 2027
    • TABLE 133: Rest of Asia-Pacific Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 134: Rest of Asia-Pacific Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 135: Rest of Asia-Pacific 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2020 & 2027
  • LATIN AMERICA
    • TABLE 136: Latin America Current & Future Analysis for Osteoporosis Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through
    • TABLE 137: Latin America Historic Review for Osteoporosis Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 138: Latin America 15-Year Perspective for Osteoporosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027
    • TABLE 139: Latin America Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 140: Latin America Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 141: Latin America 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2020 & 2027
    • TABLE 142: Latin America Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 143: Latin America Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 144: Latin America 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2020 & 2027
  • ARGENTINA
    • TABLE 145: Argentina Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 146: Argentina Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 147: Argentina 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2020 & 2027
    • TABLE 148: Argentina Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 149: Argentina Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 150: Argentina 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2020 & 2027
  • BRAZIL
    • TABLE 151: Brazil Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 152: Brazil Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 153: Brazil 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2020 & 2027
    • TABLE 154: Brazil Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 155: Brazil Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 156: Brazil 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2020 & 2027
  • MEXICO
    • TABLE 157: Mexico Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 158: Mexico Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 159: Mexico 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2020 & 2027
    • TABLE 160: Mexico Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 161: Mexico Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 162: Mexico 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2020 & 2027
  • REST OF LATIN AMERICA
    • TABLE 163: Rest of Latin America Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 164: Rest of Latin America Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 165: Rest of Latin America 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2020 & 2027
    • TABLE 166: Rest of Latin America Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 167: Rest of Latin America Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 168: Rest of Latin America 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2020 & 2027
  • MIDDLE EAST
    • TABLE 169: Middle East Current & Future Analysis for Osteoporosis Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through
    • TABLE 170: Middle East Historic Review for Osteoporosis Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 171: Middle East 15-Year Perspective for Osteoporosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027
    • TABLE 172: Middle East Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 173: Middle East Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 174: Middle East 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2020 & 2027
    • TABLE 175: Middle East Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 176: Middle East Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 177: Middle East 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2020 & 2027
  • IRAN
    • TABLE 178: Iran Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 179: Iran Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 180: Iran 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2020 & 2027
    • TABLE 181: Iran Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 182: Iran Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 183: Iran 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2020 & 2027
  • ISRAEL
    • TABLE 184: Israel Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 185: Israel Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 186: Israel 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2020 & 2027
    • TABLE 187: Israel Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 188: Israel Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 189: Israel 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2020 & 2027
  • SAUDI ARABIA
    • TABLE 190: Saudi Arabia Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 191: Saudi Arabia Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 192: Saudi Arabia 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2020 & 2027
    • TABLE 193: Saudi Arabia Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 194: Saudi Arabia Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 195: Saudi Arabia 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2020 & 2027
  • UNITED ARAB EMIRATES
    • TABLE 196: UAE Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 197: UAE Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 198: UAE 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2020 & 2027
    • TABLE 199: UAE Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 200: UAE Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 201: UAE 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2020 & 2027
  • REST OF MIDDLE EAST
    • TABLE 202: Rest of Middle East Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 203: Rest of Middle East Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 204: Rest of Middle East 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2020 & 2027
    • TABLE 205: Rest of Middle East Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 206: Rest of Middle East Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 207: Rest of Middle East 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2020 & 2027
  • AFRICA
    • TABLE 208: Africa Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 209: Africa Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 210: Africa 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2020 & 2027
    • TABLE 211: Africa Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 212: Africa Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 213: Africa 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 46